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Abstract:  Pathological  grade  is  a  useful  prognostic  factor  for  stratifying  breast  cancer  patients  into  favorable  (low-grade, 
well-differentiated tumors) and less favorable (high-grade, poorly-differentiated tumors) outcome groups. Under the current system 
of tumor grading, however, a large proportion of tumors are characterized as intermediate-grade, making determination of optimal 
treatments difficult. In an effort to increase objectivity in the pathological assessment of tumor grade, differences in chromosomal 
alterations and gene expression patterns have been characterized in low-grade, intermediate-grade, and high-grade disease. In this 
review, we outline molecular data supporting a linear model of progression from low-grade to high-grade carcinomas, as well as 
contradicting genetic data suggesting that low-grade and high-grade tumors develop independently. While debate regarding specific 
pathways of development continues, molecular data suggest that intermediate-grade tumors do not comprise an independent disease 
subtype, but represent clinical and molecular hybrids between low-grade and high-grade tumors. Finally, we discuss the clinical 
implications associated with different pathways of development, including a new clinical test to assign grade and guide treatment 
options.
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Introduction
Breast cancer is the most common cancer in women 
worldwide, and in the United States (US) is estimated 
to account for ∼26% of all new female cancer cases and 
15% of all cancer deaths among women.1 Incidence 
of breast cancer in the US has risen by approximately 
1.2% per year since 1930,2 such that one in eight 
American women now are expected to develop breast 
cancer during her lifetime. Research attempting to 
understand the molecular nature of breast cancer and 
its  progression  will  have  a  tremendous  impact  on 
costs associated with disease, and importantly, on the 
nature of diagnosis, treatment, and prevention.
Pathological  assessment  of  breast  cancer  is 
currently based on criteria such as tumor size, lymph 
node  and  hormone  receptor  status,  and  epidermal 
growth  factor  receptor  2  (HER2)  expression, 
but  pathology  alone  does  not  accurately  predict 
outcomes,  even  for  patients  with  similar  tumor 
characteristics. Recent studies suggest that, despite 
use of identical treatment modalities in patients with 
similar pathological characteristics, clinical outcomes 
can be highly variable.3 Differences in response to 
treatments such as Tamoxifen and Herceptin® likely 
reflect  heterogeneity  in  pathological  factors  such 
as estrogen receptor (ER) and HER2 status. Breast 
carcinomas  are  heterogeneous  at  the  molecular 
level, with at least five disease categories identified 
through  differential  patterns  of  gene  expression.4–6 
This extensive clinical, pathological, and molecular 
heterogeneity complicates diagnosis, prognosis, and 
treatment of patients with breast cancer.
In this review, we examine use of the Nottingham 
histological  score  in  assigning  grade  to  breast 
carcinomas and the clinical utility of the Nottingham 
score in determining patient risk and outcome. We 
outline our understanding of how genomic alterations 
contribute to histological characteristics that define 
tumor grade and the importance of molecular changes 
in shaping tumor growth and differentiation in patients 
with breast cancer. An important focus of this review 
is the ongoing debate over development of high-grade 
and low-grade breast disease, specifically on whether 
low-grade and high-grade breast carcinomas represent 
separate and distinct diseases. We present molecular 
evidence supporting a linear model of progression 
from low-grade to high-grade carcinomas, as well as 
contradicting genetic data suggesting that low-grade 
and high-grade tumors develop independently. While 
debate regarding specific pathways of development 
continues, molecular data suggest that intermediate-
grade tumors do not comprise an independent disease 
subtype, but represent clinical and molecular hybrids 
between low-grade and high-grade tumors. Finally, 
we  discuss  the  clinical  implications  of  different 
pathways of development, including a new clinical 
test to assign grade and guide treatment options.
nottingham Histological score
The  Nottingham  combined  histological  grading 
system, based on classification parameters developed 
by Bloom and Richardson7 as modified by Elston and 
Ellis,8 is currently the most widely used method for 
assessing breast tumor grade. The Nottingham score 
uses  three  components,  tubule  formation,  nuclear 
pleomorphism,  and  mitotic  count,  each  of  which 
are scored independently using criteria described in 
Table 1.9 Scores for the three components are then 
combined  and  the  cumulative  score  serves  as  the 
classifier:  low-grade  (well-differentiated)  tumors 
have a cumulative score of 3, 4, or 5; intermediate-
grade  (moderately-differentiated)  tumors  score  6 
or 7; and high-grade (poorly-differentiated) tumors 
have cumulative scores of 8 or 9.
The Nottingham grading system has clinical utility 
in  determining  patient  risk  and  outcome—patients 
with  low-grade  carcinomas  have  ∼95%  five-year 
survival compared to just 50% in patients with high-
grade disease.8,10 Although the prognostic power of 
the Nottingham score has prompted the College of 
American Pathologists to suggest using grade during 
staging,11 grade has not yet been incorporated as a 
component of tumor staging.12 Use of grade is impaired 
by  1)  the  inherent  subjectivity  associated  with  its 
assessment—concordance  between  pathologists 
ranges  from  50%–85%,13  and  2)  the  large  number 
(30%–60%)  of  tumors  classified  as  intermediate-
grade (moderately-differentiated). These tumors have 
features of both low-grade and high-grade tumors, 
making it difficult to assess risk and determine the 
most appropriate treatment option for patients.14
Genomic Discrimination of Low-  
and High-Grade Breast carcinomas
Breast  cancer  progression  can  be  defined  by  a 
non-obligatory sequence of histological changes from Heterogeneity in breast cancer tumorigenesis
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normal epithelium through atypical hyperplasia, in situ 
carcinoma,  and  finally  invasive  malignancy.15  The 
hypothesis of dedifferentiation posits that breast cancers 
evolve from well-differentiated to poorly-differentiated 
tumors  following  a  linear  model.  The  progressive 
sequence  of  dedifferentiation  is:  well-differentiated 
(grade  1)  →  moderately-differentiated  (grade  2)  → 
poorly-differentiated  (grade  3).  Support  for  a  link 
between  histological  progression  and  tumor  growth 
comes mainly from clinical studies, which have identified 
correlations  between  histological  grade  and  tumor 
size,16 or observed that impalpable carcinomas detected 
by  mammography  tend  to  be  well-differentiated.17 
In  contrast,  observations  that  recurrent  carcinomas 
tend to exhibit the same level of cellular differentiation, 
and hence the same histological grade, as the original 
primary tumor18 have led to the hypothesis that low-
grade and high-grade carcinomas reflect different disease 
entities. Although certain DNA copy number changes 
defined by comparative genomic hybridization (CGH) 
correlate with the degree of histological differentiation,19 
several molecular studies suggest that the majority of 
low-grade (well-differentiated) tumors do not progress 
to high-grade (poorly-differentiated) carcinomas. For 
example, Roylance et al20 observed distinct genomic 
differences  between  grade  I  and  grade  III  breast 
tumors;  in  particular,  loss  of  chromosome  16q  was 
significantly more frequent in grade I (65%) compared 
to grade III (16%) tumors. Likewise, Buerger et al21 
observed frequent loss of chromosome 16q in well-
differentiated invasive breast carcinomas and concluded 
that  sequential  progression  from  low-grade  to  high-
grade is unlikely because chromosomal alterations at 
16q were not maintained in higher-grade tumors.
Since the initial models of disease progression were 
published, a number of studies examining levels and 
patterns of genomic variation in breast carcinomas have 
supported the hypothesis that low-grade and high-grade 
tumors represent separate genetic diseases, based largely 
on  observations  that  the  frequency  of  alterations  at 
chromosome 16q was significantly higher in low-grade 
tumors. An allelic imbalance (AI) analysis using three 
microsatellite markers on chromosome 16q detected a 
significantly higher frequency of AI events in low-grade 
(grade 1) compared to high-grade (grade 3) tumors for 
two of the three markers.22 Likewise, microsatellite-
based data from our own group showed significantly 
higher levels of AI at chromosome 16q11-q22 in low-
grade compared to high-grade breast carcinomas.23 In 
addition, low-grade tumors contained larger alterations 
across the 23 Mb region of chromosome 16 compared to 
high-grade tumors. Only proximal markers (D16S409 
and D16S2624) on 16q had a higher frequency of AI in 
grade 1 versus grade 3 tumors, suggesting that changes 
in the 16q11-q22 region are critical in the development 
of low-grade disease (Fig. 1). Similarly, an assessment 
of  copy  number  status  across  chromosome  16q  by 
CGH, AI, and fluorescence in situ hybridization (FISH) 
demonstrated  that  low-grade  and  high-grade  disease 
were associated with different types of chromosomal 
alterations in the 16q region.24 Physical loss of large 
portions  of  chromosome  16q  was  associated  with 
low-grade  disease,  while  small  regions  of  loss  of 
heterozygosity  (LOH)  were  characteristic  of  high-
grade tumors. Further, the timing of alterations at 16q 
appeared to differ between tumor grades, with physical 
loss of 16q being an early and critical event in the 
development of low-grade breast tumors, while smaller 
alterations  of  16q  occurred  late  in  the  development 
of  high-grade  carcinomas.24  Together,  these  studies 
Table 1. Criteria for histological grading of invasive breast 
carcinomas.a
component score Description
Tubule formationb
1 Majority of tumor (75%)
2 Moderate degree (10%–75%)
3 Little or none (10%)
Nuclear 
pleomorphism
1 Small, uniform nuclear size 
and shape
2 Modest increase in size 
and variation
3 Large with marked variation
Mitotic countsc
1 7
2 8–16
3 17
aScores  for  the  three  components  are  combined  and  the  cumulative 
score classifies breast tumors as: low-grade (well-differentiated) tumors, 
3, 4, or 5; intermediate-grade (moderately-differentiated) tumors, 6 or 7; 
high-grade (poorly-differentiated) tumors, 8 or 9.
bPercent of carcinoma composed of tubular structures.
cMitotic counts vary widely with microscope type. Scores provided here 
are per 10 high-power fields on an Olympus BX41 microscope with a 
field diameter 0.54 mm.ellsworth et al
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support a model by which low-grade and high-grade 
diseases develop along separate genetic pathways, with 
alterations of chromosome 16q serving as the critical 
genetic determinant between histological grades.
Molecular  characterization  of  ductal  carcinoma 
in  situ  (DCIS)  lesions  further  supports  a  model  of 
two distinct pathways of breast disease development. 
Higher levels of chromosomal alterations have been 
detected via CGH in high-grade compared to low-
grade DCIS, with loss of 16q found almost exclusively 
in low-grade lesions.25,26 AI analysis on 100 pure DCIS 
specimens (with no detectable invasive component) 
recently  found  significantly  higher  levels  of AI  in 
the  high-grade  compared  to  low-grade  lesions—AI 
at chromosome 16q characterized low-grade lesions, 
while  alterations  at  6q25–q27,  8q24,  9p21,  13q14, 
and 17p13.1 were frequent in high-grade disease.27 
Similar patterns of chromosomal changes in in situ 
and invasive disease suggest that low-grade and high-
grade invasive breast tumors evolve directly from low-
grade and high-grade DCIS, respectively (Fig. 2).
Components of the Nottingham score
The Nottingham score uses three components, tubule 
formation, nuclear pleomorphism, and mitotic count, 
to assign histological grade, but mechanisms by which 
genomic  changes  in  breast  carcinomas  specifically 
contribute  to  these  underlying  components  are 
unknown.  When  patterns  of  AI  were  compared 
between tumors with favorable (=1) and unfavorable 
(=3)  scores  for  each  component,  significantly 
higher levels of AI were observed in samples with 
unfavorable  (high)  scores  for  all  components.28 
Tumors  with  reduced  tubule  formation  (score = 3) 
showed higher levels of AI at chromosomal regions 
11q23 and 13q12, those with high levels of nuclear 
atypia had frequent alterations at 9p21, 11q23, 13q14, 
17p13, and 17q12, and carcinomas with high mitotic 
counts were commonly altered at 1p36, 11q23, and 
13q14.  Only  region  16q11–q22  was  altered  more 
frequently  in  samples  with  low  nuclear  atypia. 
Alterations at 11q23 are common in breast tumors 
showing  reduced  tubule  formation,  high  nuclear 
atypia, and high mitotic counts, suggesting that this is 
an early genetic change in the development of poorly-
differentiated breast tumors; however, alterations at 
other chromosomal regions in poorly-differentiated 
tumors  may  specifically  influence  cell  structure, 
nuclear morphology, and cellular proliferation.
Genomic heterogeneity  
and breast cancer
The  identification  of  genomic  signatures  for  low-
grade  and  high-grade  breast  disease  provides  new 
insights into the heterogeneity of breast cancer. Under 
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Figure 1. Map of common region of LOH/Ai on chromosome 16q in low-grade 
breast carcinomas. Slight variations in the boundaries of the region have 
been reported: black bar, (20); checked bar, (23); striped bar, (24). Candidate 
genes located in the region are shown on the right. Note that mutations in 
CDH1 have been associated with invasive lobular carcinoma, but not with 
low-grade or high-grade invasive ductal carcinoma. 
Abbreviations:  RBL2,  retinoblastoma-like  2;  AKTiP,  akt-interacting 
protein; MMP, matrix metalloproteinase; CDH, cadherin; FBXL8, f-box 
and leucine-rich repeat protein 8; e2F4, e2f transcription factor 4; CTCF, 
CCCTC-binding factor; TeRF2, telomeric repeat-binding factor 2; HAS3, 
hyaluronan synthase 3.Heterogeneity in breast cancer tumorigenesis
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current models of disease progression, low-grade and 
high-grade breast carcinomas develop independently 
along different genetic pathways, thus consideration 
of breast disease without regard to tumor grade may 
mask molecular (or environmental) factors specific 
to one grade.20 For example, grade 1 DCIS has been 
shown to exhibit a significantly lower overall frequency 
of  chromosomal  changes  than  low-grade  (well-
differentiated) invasive carcinomas, but no individual 
chromosomal  regions  effectively  differentiate  low-
grade in situ from invasive disease. In contrast, high-
grade (poorly-differentiated) invasive tumors did not 
show significantly higher levels of AI than grade 3 
DCIS, but AI events at specific chromosomal regions 
(1p36 and 11q23) were significantly more frequent in 
high-grade invasive tumors compared to high-grade 
DCIS.29 Lower levels of AI in low-grade in situ lesions 
compared  to  low-grade  invasive  carcinomas  may 
reflect the protracted time-to-progression associated 
with  low-grade  DCIS.  Likewise,  increased  levels 
of AI at 1p36 and 11q23 in high-grade carcinomas 
suggest that these chromosomal regions may harbor 
genes  associated  with  invasiveness.  Therefore, 
consideration of histological grade when analyzing 
genetic data has the potential to identify molecular 
changes  associated  with  invasion  and  to  define 
molecular signatures of aggressive behavior for low-
grade and high-grade disease.
Molecular evidence  
for a Biological continuum
Stratification  of  low-grade  and  high-grade  breast 
carcinomas  into  separate  molecular  diseases  is 
based on the high frequency of alterations observed 
for chromosome 16 in low-grade tumors and a low 
frequency of 16q alterations in high-grade tumors. 
To localize genes involved in low-grade IDCA, and 
to  refine  regions  of  chromosome  16  that  may  be 
important to the development of high-grade disease, 
Roylance et al characterized 40 low-grade (grade 1) 
and 17 high-grade (grade 3) IDCA using CGH with 
nearly contiguous coverage of chromosome 16q.30 The 
majority of low-grade tumors showed large deletions 
of 16q, while high-grade tumors were more frequently 
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G1 G3
+1q
–16q
–9p
+11q
–13q
–17p
+17q
invasive carcinoma
In situ disease
Low-grade
invasive
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invasive
In situ invasive transition
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+1q
+8q
+16p
+17q
+20q
–16q
–1p36
–8p
–11q23
–13q
–18q
Figure 2. Models of genomic changes depicting pathways of development for low-grade and high-grade breast carcinomas. Low-grade DCiS and iDCA 
are genetically distinct from high-grade in situ and invasive disease. Alterations of chromosomes 1q, 8q, 16p, and 16q are associated with low-grade 
disease, while high-grade tumors demonstrate higher levels of alterations at a number of regions throughout the genome. 
Abbreviations: G1, grade 1; G3, grade 3; iDCA, invasive ductal carcinoma.ellsworth et al
82  Clinical Medicine: Oncology 2009:3
characterized  by  multiple,  small  chromosomal 
alterations, including copy number gains in this region. 
Because many regions demonstrated loss and gain of 
certain sections, chromosome 16q may be inherently 
unstable  and  many  of  these  regions  may  contain 
secondary, rather than causative, alterations. Based 
on this data, and the identification of copy number 
gains not previously detected, Roylance et al30 suggest 
that loss of chromosome 16q is an early event in the 
development of low-grade tumors, and postulate that 
high-grade carcinomas evolve from low-grade tumors 
by  the  accumulation  of  subsequent  chromosomal 
alterations, such as small breaks and amplifications. 
These observations question the role of chromosome 
16q deletions as the key to defining low- and high-
grade genetic pathways of development.
The Nottingham grading system, used to assign 
histological grade to invasive carcinomas, does not 
adequately describe internal variation in the degree 
of  differentiation  within  tumors.  Although  most 
pathologists  rely  on  nuclear  grade,  either  alone  or 
in  combination  with  central  necrosis,  to  classify 
DCIS,  one  recent  attempt  to  quantify  histological 
diversity in 120 pure DCIS lesions found that ∼46% 
of cases showed localized variability in histological 
grade.  Nearly  one-third  of  lesions  with  internal 
grade differences demonstrated further diversity for 
a panel of immunohistochemistry markers including 
ER, GATA-binding protein 3 (GATA3), and HER2.31 
The  authors  concluded  that  higher-grade  DCIS 
gradually evolve from lower-grade in situ lesions by 
random  accumulation  of  genetic  mutations.  These 
studies  hypothesize  that  low-grade  and  high-grade 
breast carcinomas are not necessarily unique genetic 
diseases.  Under  this  model,  cells  with  the  most 
aggressive/poorly-differentiated  characteristics  tend 
to become the dominant cell type during progression 
from low-grade to high-grade carcinomas.
Molecular Classification 
of Intermediate-Grade Tumors
Molecular  and  pathological  changes  have  been 
associated  with  low-grade  and  high-grade  breast 
carcinomas, which represent the extremes of histological 
differentiation. Conversely, development of a model for 
intermediate-grade breast tumors presents a particular 
challenge  because  intermediate-grade  carcinomas 
contain a blend of histological features common to 
both low-grade (well-differentiated) and high-grade 
(poorly-differentiated)  tumors.  Because  carcinomas 
with intermediate-grade histology represent 30%–60% 
of all invasive breast cancers, improved understanding 
of the genetics of these tumors is critical in determining 
the optimum course of treatment for the large group of 
patients with intermediate pathological features.32
Patterns of genetic changes usually do not differ 
significantly between intermediate-grade and high-grade 
carcinomas, supporting the idea that intermediate-grade 
invasive breast tumors develop from either grade 2 or 
grade 3 DCIS. Further studies of genomic alterations 
in  breast  tumors  of  different  histological  grades 
have  shown  that  although  genetic  changes  were 
more frequent in grade 3 tumors, alterations of one 
specific chromosomal region (16q) were significantly 
lower  (P  0.01)  in  high-grade  (26%)  compared  to 
intermediate-grade (54%) tumors.33 Thus it appears that 
intermediate-grade carcinomas may represent a mixture 
of histological characteristics and may develop along 
two independent genetic pathways, one characterized 
by loss of chromosome 16q, few genomic alterations, 
and high rates of diploidy, while the other pathway 
is  characterized  by  high  homology  with  high-grade 
tumors.
In our ongoing studies of intermediate-grade breast 
carcinomas,  we  observed  that  clinicopathological 
characteristics and overall levels of genomic alterations 
in grade 2 tumors were generally intermediate compared 
to  low-grade  and  high-grade  disease.23  Specifically, 
47% of the intermediate-grade tumors showed patterns 
of genomic alterations similar to high-grade tumors, 
while 11% had a low-grade signature where AI was 
detected only at chromosome 16q. Of note, 24% of 
cases showed genetic features representing a mixture 
of low-grade and high-grade disease, while 18% had a 
unique genomic profile not observed in either high- or 
low-grade tumors. These data suggest that intermediate-
grade carcinomas should not be classified as a discrete 
disease type, but represent a blend of low-grade and 
high-grade diseases.
Gene expression analysis has been widely used 
to identify genetic profiles associated with different 
stages  of  breast  cancer  development.  Using  laser 
microdissection to isolate pure populations of tumor 
cells and prevent cross-contamination from stroma 
or  co-occurring  lesions,  histological  grade  rather 
than pathological stage, was found to correlate with Heterogeneity in breast cancer tumorigenesis
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significantly different patterns of gene expression.34 
A subset of samples showed gene expression signatures 
that were distinctly grade-1-like or grade-3-like; most 
intermediate-grade  tumors  exhibited  a  mixed  low- 
and high-grade gene expression profile. Similarly, an 
expression signature from only five genes—barren 
homologue—Drosophila  (BRRN1),  hypothetical 
protein FLJ11029, chromosome 6 open reading frame 
173  (C6orf173),  serine/threonine-protein  kinase  6 
(STK6), and maternal embryonic leucine zipper kinase 
(MELK)—has been shown to discriminate low-grade 
from high-grade tumors with ∼95% accuracy.35 When 
applied to intermediate-grade tumors, ∼66% (83/126) 
were reclassified as low-grade-like (G2a) and 34% 
(43/126) as high-grade-like (G2b). Only five samples 
had true intermediate gene expression scores. Survival 
outcomes for the G2a and G2b groups were similar to 
those in patients with grade 1 and grade 3 tumors, 
respectively.  Further  investigation  of  intermediate-
grade  carcinomas  classified  as  G2a  and  G2b 
demonstrated marked heterogeneity between the two 
groups, suggesting that intermediate grade tumors do 
not represent an independent disease subtype and that 
the G2a and G2b classifications should be considered 
separate pathobiological entities.35
Recognizing the inherent subjectivity in assigning 
histological grade and the need to better characterize 
intermediate-grade  tumors,  researchers  have  begun 
to  analyze  combined  gene  expression  data  sets 
from  primary  breast  tumor  samples  derived  from 
multiple sources. These approaches have led to the 
development of a gene expression grade index (GGI), 
based  on  97  genes,  which  summarizes  molecular 
differences  between  low-grade  and  high-grade 
breast tumors.14 Similar to earlier results,34 the GGI 
partitions  intermediate-grade  carcinomas  into  low-
grade and high-grade clusters; with un-clustered cases 
representing a mixture of the two grades.
clinical Implications
Molecular  data  (DNA  and  RNA)  suggest  that 
intermediate-grade  invasive  breast  cancer  is  not  a 
discrete disease, but represents a blend between low-
grade and high-grade tumors. However, whether poorly-
differentiated  tumors  arise  from  well-differentiated 
carcinomas,  or  whether  low-grade  and  high-grade 
tumors develop along independent genetic pathways 
remains  unclear.  Although  multiple  studies  have 
identified significant differences in gene expression 
between low-grade and high-grade disease,14,34,35 gene 
and protein expression profiles are transient, reflecting 
biological  conditions  in  the  tumor  at  the  time  of 
excision, rather than an evolutionary history of tumor 
development. In contrast, chromosomal changes can 
be  very  useful  for  modeling  disease  progression. 
Continuing improvements in technologies to measure 
chromosomal  alterations,  such  as  copy  number 
changes  assessed  by  large-scale  single-nucleotide 
polymorphism (SNP) arrays,36 may provide the tools 
necessary to determine the role of chromosome 16q 
in the development of low-grade tumors and further 
examine  the  development  of  low-grade  as  well  as 
high-grade breast carcinomas.
Determining  relationships  among  tumors  of 
different histological grades has important clinical 
implications  for  estimating  risk  and  defining 
treatment  options  in  patients  with  breast  disease. 
For  example,  atypical  ductal  hyperplasia  (ADH) 
specimens typically share a gene expression profile 
with grade 1 disease and tend to cluster with low-
grade DCIS and well-differentiated invasive cancer.34 
Thus,  ADH  may  represent  a  precursor  lesion, 
specifically to low-grade breast cancer. Should low-
grade disease be genetically distinct from high-grade, 
patients diagnosed with ADH could be considered 
lower-risk, reflecting the less aggressive phenotype 
of low-grade disease. Similarly, under a model of 
tumor  progression  from  low-grade  to  high-grade 
through histological de-differentiation, identification 
of molecular changes that promote progression may 
provide  molecular  targets  for  the  development  of 
therapeutics to block the progression from low-grade 
to high-grade (aggressive) tumors.
Development of molecular signatures that closely 
correlate  with  histological  differentiation  may 
improve the assessment of tumor grade. At present, 
debate  continues  within  the  pathology  community 
over the best way to assign histological grade. Some 
studies  suggest  that  a  two-tiered  grading  system 
comprised  of  nuclear  pleomorphism  and  mitotic 
counts is superior to the current tripartite system that 
includes  tubule  formation.9,37  In  contrast,  research 
suggests that a composite score based on a 7-point 
scale (range 3–9) is more accurate than the current 
system  that  converts  the  cumulative  scores  from 
tubule formation, nuclear pleomorphism, and mitotic ellsworth et al
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counts  to  a  3-grade  system.38  For  example,  while 
tumors with a composite score of 6 or 7 would be 
classified as intermediate-grade, those with a score 
of 7 have a prognosis similar to high-grade tumors. 
It is possible that tumors with a score of 6 correspond 
to  the  G2a  tumor  group  and  those  with  a  score 
of 7 to the G2b tumor group defined by Ivshina et al35 
suggesting that tumors with scores of 6 and 7 should 
be  considered  separately  when  making  treatment 
decisions.
Finally,  molecular  profiles  such  as  the 
OncotypeDX™  (Genomic  Health,  Redwood  City, 
CA) and MammaPrint® (Agendia, Amsterdam, The 
Netherlands) are now being used more frequently as 
clinical tools to determine treatment for certain groups 
of patients. For example, the OncotypeDX™ can be 
used  to  make  decisions  about  chemotherapy  after 
surgery for women with node-negative, ER-positive 
breast cancer. In 2008, Ipsogen (http://www.ipsogen.
com/) developed the MapQuant Dx™ Genomic Grade 
test based on the GGI discussed above.14 This test is 
being marketed as the first microarray-based diagnostic 
test to measure tumor grade. With the reported ability 
to  classify  80%  of  intermediate-grade  tumors  as 
either low-grade or high-grade, the MapQuant assay 
may be useful in guiding treatment options, possibly 
sparing patients with grade 1 or grade 1-like tumors 
unnecessary  treatments,  while  identifying  patients 
who would benefit from chemotherapy.32
summary
Molecular characterization of breast tumors at both 
the DNA and RNA levels suggests that intermediate-
grade carcinomas do not represent an independent 
disease  subtype,  but  instead  share  clinical  and 
molecular  features  of  low-grade  and  high-grade 
tumors. In contrast, debate continues as to whether 
poorly-differentiated  (high-grade)  tumors  evolve 
from  well-differentiated  (low-grade)  tumors  or 
whether  low-grade  and  high-grade  carcinomas 
represent  discrete  diseases  that  develop  along 
separate  genetic  pathways.  While  efforts  continue 
to improve our understanding of biological factors 
influencing  the  development  of  low-,  intermediate-, 
and high-grade tumors, clinical uses of molecular 
assays are providing new ways to assign histological 
grade and guide treatments for patients with breast 
cancer.
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